Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The study will be conducted in two parts. The first is a parallel-group design, evaluating
doses of 40 mg, 80 mg or 120 mg BCX-4208. The second part is planned as a dose-escalation
study, evaluating higher doses including 160 mg, 240 mg and 320 mg BCX-4208. The study's
primary endpoint is the change in uric acid in the blood compared to baseline measurement
prior to treatment, assessed on Day 22.